Variant effect prediction was performed using SnpEff v3.6 (Cingolani, Platts, Wang, Coon, & 1 0 2 Nguyen, 2012) using GRCh37.34 genome version, subsequently variants were annotated to dbSNP 1 0 3 v146 and to dbNSFP v2.4 (Liu, Jian, & Boerwinkle, 2013) using same suite. 1 0 4
The following chain of filters was applied to the variant set: GATK VQSLOD > 0, predicted 1 0 5 change in coding sequence, segregation according to a dominant model, rarity in the population 1 0 6 (COMMON = 0 in dbSNP build 137), predicted to be damaging according to SIFT (Kumar, 1 0 7
Henikoff, & Ng, 2009) and Polyphen (Adzhubei et al., 2010) . Genes were prioritized using the 1 0 8
Phenolyzer platform (Yang, Robinson, & Wang, 2015) . 1 0 9 1 1 0
Expression Plasmids 1 1 1
The Human GLI2 cDNA clone was obtained from Addgene (pCS2-hGli2 #17648 (Roessler et al., 1 1 2 2005)) For N-terminal GFP tagging of GLI2, hGLI2 cDNA was inserted at the 3'-end of EGFP in 1 1 3 the CMV expression vector pN1-EGFP (Clontech) using standard PCR-cloning. GeneArt 1 1 4
Mutagenesis kit (Thermo) was used to introduce the deletion c.3493delC (p.P1167LfsX52) into 1 1 5
GFP-tagged wild-type GLI2 expression construct using the following primers: 1 1 6
Forward 5'-CCAGCCAGGTGAAGCCTCCACCTTTCCTCAGGGCAACCTG-3' 1 1 7
Reverse 5'-CAGGTTGCCCTGAGGAAAGGTGGAGGCTTCACCTGGCTGG-3' 1 1 8 1 1 9
Western Blotting 1 2 0
HEK293T cells (AD-293 cell line) were maintained in DMEM supplemented with 10% FBS, 1% L-1 2 1
Glutamine, 1% Penicillin/Streptomycin. Cells transfected with the GFP-tagged constructs or pN1-1 2 2 EGFP control for 36 hrs using Lipofectamine 2000 (Thermo) were lysed on a nutator for 30 min at 1 2 3 4°C in lysis buffer (NaCl 150mM, EDTA 2mM, Tris-HCl pH7.5 50mM, Triton 1%) supplemented 1 2 4
with protease and phosphatase inhibitor cocktails. After clarification by centrifugation at 13,000 g 1 2 5
for 10 min at 4°C, 20μg of total protein lysate were analyzed by SDS-PAGE followed by 1 2 6
immunoblot with rabbit anti-GFP antibody (1:1000; Thermo) and rabbit anti-GAPDH (1:5000; Cell 1 2 7
Signaling). Detection was performed by standard chemiluminescence with ECL Plus Western 1 2 8
Blotting Substrate (Pierce/Thermo). Thermo) with the following primer sets: The same plasmids mixed at 2:1:1 ratio (GLI2/mock GFP plasmids:8x-GLI-BS-Luc:Renilla Luc) 1 6 0
were electroporated "in-ovo" into neural progenitor cells in the neural tube of HH stage 13-14 chick Proband is a 6 year old female with neonatal panhypopituitarism (HP:0000871), prominent hormone deficiency (GHD) (HP:0000824)], unilateral hexadactyly (HP:0001162), and ectopic 1 7 9
pituitary posterior lobe (HP:0011755). After further investigation, hexadactyly (HP:0001162) was 1 8 0 described in the paternal grandfather, while GHD (HP:0000824) and hypopituitarism (HP:0040075) 1 8 1
were identified in the paternal uncle who did not exhibit hand anomalies ( Figure 1A) . 1 8 2
The proband was previously tested negative for mutations in candidate disease-linked genes 1 8 3 POUF1, PROP1, HESX1, LHX3 and GLI3. Exome sequencing was performed on the trio ( Figure 1A) at average target coverage of 30x for 1 8 7 each sample (Table S1 ). After variant calling, 130 rare or novel variants in 125 genes were found 1 8 8
segregating according to a dominant model and affecting coding sequences. Once filtered for 1 8 9
putative pathogenicity, 40 variants in 40 genes were retained (Table S2 ). Candidate genes were 1 9 0 prioritized based on their association with the clinical phenotypes of the patients using Phenolyzer 1 9 1
software. This analysis unambiguously identified GLI2 as the top-scoring gene, while other 1 9 2 candidates (WDR34, DPAGT1, ASXL1) already known to be associated with query phenotypes were 1 9 3 ranked significantly lower ( Figure 1B ). Both the proband and her father were found to carry a novel 1 9 4 heterozygous mutation caused by the deletion c.3493delC in the GLI2 gene, leading to a frameshift 1 9 5
and premature stop of translation at residue 1218 (p.P1167LfsX52). 1 9 6 1 9 7
The mutation p.P1167LfsX52 converts GLI2 into a dominant-negative transcriptional repressor 1 9 8
The frameshift mutation c.3493delC in GLI2 truncates the C-terminal portion of the transactivation 1 9 9
domain required for transcriptional activity (p.P1167LfsX52, Figure 2A ). To determine whether 2 0 0 this truncation alters GLI2 function, we generated GFP-tagged constructs of either wild-type GLI2 2 0 1 or the p.P1167LfsX52 mutant (hereafter GLI2 MUT ) and examined their functional properties using 2 0 2 cell-based assays. As predicted, GLI2 MUT revealed by western blotting in transfected HEK293 cells 2 0 3 was smaller than the wild-type protein (~129kDa vs. 167kDa; ~156kDa vs. 194 kDa after GFP 2 0 4 fusion) ( Figure 2B ). However, the subcellular distribution of GLI2 MUT expressed in NIH-3T3 2 0 5 mouse fibroblasts, which respond to SHH, was similar to that of wild-type GLI2: both proteins were 2 0 6 found in the cytoplasm as well as the nucleus in untreated cells and accumulated within the nucleus 2 0 7
following stimulation with SHH ( Figure 2C-F') . Nevertheless, despite normal nuclear targeting, 2 0 8 GLI2 MUT was unable to induce expression of the transcriptional targets of SHH signaling GLI1 and 2 0 9
Ptch1, whose mRNA levels were instead substantially higher in SHH-treated cells overexpressing 2 1 0
wild-type GLI2 relative to mock-transfected controls ( Figure 2G and H) .
To directly investigate the effects of the p.P1167LfsX52 mutation on GLI2 transcriptional activity, 2 1 2
we assessed the ability of GLI2 MUT to stimulate a GLI-dependent reporter construct (8xGliBS-Luc) 2 1 3
in which a promoter containing tandem GLI responsive elements drives expression of firefly 2 1 4 luciferase upon activation of the Hedgehog pathway (Sasaki et al., 1999) . In NIH-3T3 cells, 2 1 5 overexpression of wild-type GLI2 increased reporter activity in a ligand-independent manner to an 2 1 6 extent comparable to control cells treated with SHH. Conversely, the basal levels of reporter 2 1 7
activity were significantly lower in cells transfected with GLI2 MUT and did not show the expected 2 1 8 increase after SHH stimulation ( Figure 2I ). control). Electroporation of wild-type GLI2 led to robust induction of reporter activity independent 2 2 5 of SHH stimulation, whereas GLI2 MUT caused a considerable reduction in luciferase levels 2 2 6 compared to control cells at all ligand concentrations tested, indicating that the mutant protein 2 2 7 suppresses transcription mediated by endogenous GLI factors ( Figure 2J ). 2 2 8
In conclusion, the truncated mutant p.P1167LfsX52 functions as a transcriptional repressor that 2 2 9
exerts dominant-negative effects on GLI-dependent gene expression. Functional studies based on cellular assays demonstrated that the frameshift mutation 2 3 6 p.P1167LfsX52 truncates the C-terminal transactivation domain of GLI2 generating a 2 3 7
transcriptional-repressor form that retains the ability to translocate into the nucleus in response to 2 3 8 SHH but exhibits dominant-negative activity. As a result, we observed a significant inhibition of 2 3 9
GLI reporter levels in cells expressing GLI2 p.P1167LfsX52, indicating that the activity of wild-2 4 0 type GLI proteins is suppressed by the mutant variant. Dominant-negative activity was reported for 2 4 1 other pathogenic variants of GLI2 with deletions in the activation domain (Roessler et al., 2005) . 2 4 2
The inhibitory effect was found to require integrity of the DNA-binding and amino-terminal 2 4 3 transcriptional repressor domains (Flemming et al., 2013; Roessler et al., 2005) , which are intact in 2 4 4 GLI2 p.P1167LfsX52. To inhibit positive GLI function, C-terminally truncated variants may 2 4 5 compete with and displace wild-type GLI2 from target sites and/or form inactive complexes with 2 4 6 the activating forms. 2 4 7
While GLI2 mutations were originally identified in patients with HPE and midline abnormalities, 2 (Roessler et al., 2003; 2005) , more recently it became clear that GLI2 variants are often associated 2 4 9
